Fractyl reports 80% weight-loss retention with Revita
Fractyl Health (NASDAQ:GUTS) reported that its Revita procedure met a six-month co-primary endpoint in the 308-patient REMAIN-1 study, showing improved weight maintenance after GLP-1 treatment discontinuation.











